Human monoclonal antibodies that bind hepatitis C virus (HCV) E1
US7250166B2 · kind B2 · utility
8Cited by
4References
4Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Jan 14, 2002 |
| Grant date | Jul 31, 2007 |
| Priority date | — |
| Expiry date | Jan 19, 2022 |
Classification
- Technology area (CPC C)Chemistry; Metallurgy
- CPC primaryC07K2317/56
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
The present invention relates to materials and methods for treatment of hepatitis C. More closely, the invention relates to human monoclonal antibodies against HCV E1 antigen, to a reagent comprising such antibodies, and to vaccine compositions comprising such antibodies. Futhermore, the invention relates to a method of treating or preventing HCV infection by administration of a vaccine composition comprising the monoclonal antibodies of the invention.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.